Fibrates and Gallbladder Health: An Educational Overview

Important Notice

This page is provided for educational purposes only. It is not medical advice, and nothing on this page should be used to make treatment decisions. Never stop taking a prescribed medication or change your regimen without guidance from your prescribing physician. If you have concerns about digestive symptoms or gallbladder health while taking a fibrate, speak with your doctor.

---

What Are Fibrates?

Fibrates, also called fibric acid derivatives, are prescription medications used primarily to lower elevated triglyceride levels and, in some cases, to modestly raise HDL cholesterol. They are often prescribed when triglycerides remain high despite lifestyle changes or when statin therapy alone is not sufficient.

Common fibrates include:

• Fenofibrate (Tricor®, Antara®, Lipofen®)
• Gemfibrozil (Lopid®)
• Bezafibrate (available in some countries outside the United States)
• Clofibrate (Atromid-S®; now largely discontinued)

Clofibrate is no longer commonly prescribed, but it played an important role in early research on fibrates and gallbladder health and is discussed below for that reason.

---

How Fibrates May Affect the Gallbladder

Compared with many other medication-gallbladder associations, the fibrate literature includes a better-developed mechanistic explanation.

The Role of CYP7A1

Cholesterol 7α-hydroxylase (CYP7A1) is the rate-limiting enzyme in the primary pathway by which the body converts cholesterol into bile acids. Bile acids help keep cholesterol dissolved in bile. When bile acid levels are reduced relative to cholesterol, bile can become supersaturated with cholesterol — a condition that increases the lithogenic potential of bile, meaning it becomes more likely to form crystals or stones over time.[1][2]

Proposed Mechanism

Fibrates activate PPARα (peroxisome proliferator-activated receptor alpha) receptors in the liver. Published research has shown that this activation can downregulate key enzymes involved in bile acid synthesis, including CYP7A1, reducing bile acid production.[1] With fewer bile acids available to help solubilize cholesterol in bile, the balance may shift in a direction associated with greater stone-forming potential.[1][2]

It is important to note that while this mechanism is supported by enzyme-level and biliary lipid research, the pathway from altered bile acid synthesis to individual gallstone formation involves additional variables. Not everyone taking a fibrate develops gallstones, and the research on outcomes reflects population-level associations rather than individual predictions.

---

What the Research Has Found

Clofibrate

Clofibrate, the earliest and most extensively studied fibrate, produced the strongest gallstone signal in the literature. The World Health Organization Cooperative Trial on Primary Prevention of Ischaemic Heart Disease — a large controlled trial conducted in the 1970s — reported a significantly elevated rate of gallstone formation and cholecystectomy in the clofibrate-treated group compared with controls.[3] This finding contributed to clofibrate's decline in clinical use and helped establish class-level concern about fibrates and bile.

Fibrates as a Class

Subsequent research examined whether the gallstone association observed with clofibrate also applied to newer fibrates. Published reviews have concluded that fibrates as a class are associated with increased gallstone risk compared with non-users, although the magnitude of the association varies across agents and study populations.[4] Clofibrate carried the largest signal; currently prescribed fibrates such as fenofibrate appear to carry a lower but still documented risk.

Taken together, the published evidence suggests a consistent association between fibrate use and increased gallstone risk, with the strongest data coming from clofibrate studies and supporting mechanistic evidence from biliary lipid research on newer agents. These are population-level associations and do not predict outcomes in any individual patient.[3][4]

Statins: A Note for Context

Research on statins and gallbladder health has produced a different picture. Some observational studies have suggested that statin use may be associated with a lower risk of gallstone disease, potentially through a different effect on cholesterol metabolism.[5] This distinction may be worth discussing with your physician if you are taking both a statin and a fibrate.

---

Factors That May Increase Risk

Based on the published literature, gallbladder effects from fibrates may be more likely or more pronounced in people who:

• have a personal or family history of gallstones or biliary sludge
• have other established gallstone risk factors, including obesity or a history of rapid weight loss
• are taking fibrates at higher doses or for longer durations
• are taking other medications that may affect bile metabolism, including estrogen-containing therapies

These are risk factors drawn from the general and fibrate-specific literature. They are not predictive of individual outcomes, and many people on long-term fibrate therapy do not develop gallbladder problems.

---

Digestive Symptoms Worth Discussing With Your Doctor

Gallbladder changes often produce no symptoms in their early stages. Some people taking fibrates do report digestive changes that may warrant evaluation. These symptoms are nonspecific and can have many causes, but they are worth discussing with your physician if they are new, persistent, or worsening:

• new sensitivity to fatty or rich foods
• discomfort in the upper right abdomen, particularly after eating
• bloating that seems disproportionate to what was eaten
• changes in stool color toward lighter or clay-like shades
• nausea or a feeling of fullness after meals

Please Consult Your Doctor First

These symptoms can reflect many different conditions, most of them unrelated to gallbladder disease. If you are experiencing any of them while taking a fibrate, your prescribing physician should be your first point of contact. They can evaluate your symptoms in the context of your medical history and determine whether further workup is appropriate. If gallbladder involvement is suspected, evaluation may include abdominal imaging such as ultrasound.

---

About Bile Support Supplements

Some people, for a variety of reasons not limited to medication use, experience changes in fat digestion and look into dietary supplements formulated to support bile availability during digestion.

Gallavance is a dietary supplement formulated with bile acids and phospholipids in delayed-release capsules designed to open in the intestine, where fat emulsification takes place.

FDA Disclaimer

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Gallavance is not formulated as a fibrate adjunct, and it is not a treatment for gallbladder disease or any other medical condition. If you are taking a fibrate or any other prescription medication and are considering a bile support supplement, that conversation should happen with your prescribing physician before you begin. Your care team needs a complete picture of everything you are taking.

Gallavance Original

A bile-anchored formula containing ox bile extract, phosphatidylcholine, L-taurine, artichoke extract, dandelion root, and ginger extract.

Gallavance Plant-Based

A plant-based formula designed for consumers seeking a bile-support approach without animal-derived bile ingredients.

Supplement Notice

Gallavance is a dietary supplement, not a medication. Gallavance's ingredients have not been specifically studied alongside fibrates or other lipid-lowering therapies. Always consult your prescribing physician before adding any supplement to your regimen.

---

Frequently Asked Questions

Do fibrates cause gallstones?

Published research has found an association between fibrate use and increased gallstone risk, with the strongest historical evidence coming from clofibrate studies.[3][4] The proposed mechanism — reduced bile acid synthesis through fibrate-related effects on key hepatic pathways — is supported by enzyme-level and biliary lipid research.[1][2] However, these are population-level associations. They do not mean that everyone taking a fibrate will develop gallstones, and they do not predict individual outcomes.

Should I stop my fibrate if I'm concerned about my gallbladder?

No. Never discontinue a prescribed medication without consulting your physician. Elevated triglycerides carry their own health risks, and your doctor prescribed a fibrate because the clinical benefit was judged to outweigh the risks in your situation. If you have concerns about gallbladder health, raise them directly so your physician can decide whether monitoring or further evaluation is appropriate.

Are statins also associated with gallbladder problems?

The statin literature points in a different direction from fibrates. Some observational studies have suggested that statin use may be associated with reduced gallstone risk.[5] If you are taking both a statin and a fibrate, the combined effect on bile metabolism is a reasonable topic to discuss with your physician.

Can I take a bile support supplement while on a fibrate?

Gallavance's ingredients have not been specifically studied alongside fibrates. Because your physician prescribed a fibrate to manage a specific lipid issue, they should be informed about everything else you are taking. Consult your prescribing physician before adding any supplement to your regimen.

Is this page suggesting that Gallavance addresses fibrate side effects?

No. This page is an educational resource about published research on fibrates and gallbladder health. Gallavance is a dietary supplement used by people who, for many different reasons, are interested in supporting fat digestion. It is not formulated or marketed as a fibrate adjunct, and no claim is being made here that it addresses fibrate side effects or gallstone risk.

---

Research References

[1] Post SM, et al. Fibrates suppress bile acid synthesis via peroxisome proliferator-activated receptor-α-mediated downregulation of cholesterol 7α-hydroxylase and sterol 27-hydroxylase. Arterioscler Thromb Vasc Biol. 2001;21(12):1840–1845.

[2] Schoenfield LJ, et al. Effects of fibric acid derivatives on biliary lipid composition. Arteriosclerosis. 1987;7(5):497–503.

[3] Committee of Principal Investigators. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J. 1978;40(10):1069–1118.

[4] Pereira SP, et al. Drug-induced gallbladder disease: incidence, aetiology and management. Drug Saf. 1994;11(3):198–208.

[5] Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL. Statin use and the risk of cholecystectomy in women. JAMA. 2009;302(18):2001–2007.

---

← Back to Medications and Gallbladder Health